Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $191.9 million.

  • BridgeBio Pharma's Shares Outstanding (Weighted Average) rose 177.38% to $191.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.9 million, marking a year-over-year increase of 177.38%. This contributed to the annual value of $186.1 million for FY2024, which is 1430.32% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Shares Outstanding (Weighted Average) is $191.9 million, which was up 177.38% from $190.5 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Shares Outstanding (Weighted Average) high stood at $191.9 million for Q3 2025, and its period low was $138.6 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $164.1 million, with a median of $160.5 million in 2023.
  • As far as peak fluctuations go, BridgeBio Pharma's Shares Outstanding (Weighted Average) skyrocketed by 2499.54% in 2021, and later fell by 4.74% in 2022.
  • BridgeBio Pharma's Shares Outstanding (Weighted Average) (Quarter) stood at $144.4 million in 2021, then increased by 2.16% to $147.5 million in 2022, then increased by 10.39% to $162.8 million in 2023, then rose by 14.3% to $186.1 million in 2024, then increased by 3.11% to $191.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $191.9 million in Q3 2025, compared to $190.5 million in Q2 2025 and $190.1 million in Q1 2025.